O'Shares Investment Advisers’s AbbVie ABBV Stock Holding History

O'Shares Investment Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-53,323	Closed	-$8.64M	–	3
2022 Q1	$8.64M	Buy	53,323 +2,982	+6%	+$433K	0.68%	35
2021 Q4	$6.82M	Buy	50,341 +3,662	+8%	+$433K	0.49%	53
2021 Q3	$5.04M	Sell	46,679 -1,006	-2%	-$115K	0.37%	81
2021 Q2	$5.37M	Buy	47,685 +1,160	+2%	+$131K	0.38%	82
2021 Q1	$5.04M	Sell	46,525 -189	-0.4%	-$20.2K	0.37%	82
2020 Q4	$5M	Buy	46,714 +4,444	+11%	+$427K	0.38%	84
2020 Q3	$3.7M	Buy	+42,270	New	+$3.98M	0.39%	80
2020 Q2	–	Sell	-83,819	Closed	-$6.39M	–	277
2020 Q1	$6.39M	Sell	83,819 -65	-0.1%	-$5.54K	1.14%	22
2019 Q4	$7.43M	Buy	83,884 +5,454	+7%	+$453K	1.02%	24
2019 Q3	$5.94M	Buy	78,430 +24,236	+45%	+$1.66M	0.89%	25
2019 Q2	$3.94M	Buy	54,194 +3,162	+6%	+$249K	0.63%	37
2019 Q1	$4.11M	Buy	51,032 +1,290	+3%	+$106K	0.7%	32
2018 Q4	$4.59M	Buy	+49,742	New	+$4.37M	0.88%	28

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

O'Shares Investment Advisers's ABBV Position: Q2 2022 in Review

O'Shares Investment Advisers sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 53,323 shares — an estimated $8.64M sold.

O'Shares Investment Advisers first reported a position in ABBV in Q4 2018 and held it in 13 quarters. The position peaked at $8.64M in Q1 2022. 3,005 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

O'Shares Investment Advisers reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
O'Shares Investment Advisers sold 53,323 AbbVie shares in Q2 2022, an estimated $8.64M.
O'Shares Investment Advisers first reported a position in AbbVie in Q4 2018 and held it in 13 quarters.
O'Shares Investment Advisers's AbbVie position peaked at $8.64M in Q1 2022.
3,005 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on O'Shares Investment Advisers's 13F filing for Q2 2022.